Ava Presents at TechCrunch Disrupt San Francisco

Ava Presents at TechCrunch Disrupt San Francisco

Ava chosen among the world’s most innovative startups to present at TechCrunch Disrupt San Francisco

Ava is the world’s first bracelet that precisely detects fertile days. Today, the product is presented at
TechCrunch Disrupt San Francisco, one of the world’s most important tech events. The product has the
potential to revolutionize women’s health.

Every third couple has trouble conceiving

Knowing which days are fertile is critical to get pregnant. Today’s solutions to determine ovulation are
inconvenient, imprecise, or outdated. This makes timing one of the key reasons that many couples have
trouble to conceive.

Ava is a convenient bracelet worn by women at night. It continuously measures nine physiological
parameters and records three million data points every night. The patented technology has been
clinically tested at the University Hospital of Zurich / Switzerland.

Breakthrough due to multi-disciplinary team

The Ava bracelet has been developed by leading physiologists, gynecologists, data scientists, sensor
companies, and veterans in the wearable technology industry. The joint expertise lead to an approach
that has the potential to become a standard in reproduction medicine. “The fact that our bracelet is not
only working from a technical perspective, but also attractively looking and well accepted by end
customers, will be critical to quickly scale it in the market”, says Lea von Bidder, Co-Founder of Ava.

On the basis of the positive results, Ava is now building up partnerships with business partners. After
having produced two prototype series, Ava is now in the industrialization phase to produce large
quantities at high quality.

From conceiving to pregnancy and contraception

While the first product offering will be geared towards couples that want to have a baby, the bracelet
will become relevant for other use cases. “With five billion data points, Ava has built the biggest
database of physiological data correlated with ovulatory information”, says Pascal Koenig, Co-Founder
of Ava. “On this basis, we will be able to scale in various services during pregnancy. Furthermore, we
strive to establish Ava as a non-hormonal alternative for contraception over the coming years. After
having won several awards in Switzerland, it is great to see that our solution creates interest on a global
scale.”

By continuing to use the site, you agree to the use of cookies. More information Accept

This site is using first and third party cookies to be able to adapt the advertising based on your preferences. If you want to know more or modify your settings, click here. By continuing to use the site, you agree to the use of cookies.